| Year |
Citation |
Score |
| 2021 |
Saunders AM, Burns DK, Gottschalk WK. Reassessment of Pioglitazone for Alzheimer's Disease. Frontiers in Neuroscience. 15: 666958. PMID 34220427 DOI: 10.3389/fnins.2021.666958 |
0.345 |
|
| 2020 |
Pytte J, Flynn LL, Anderton RS, Mastaglia FL, Theunissen F, James I, Pfaff A, Koks S, Saunders AM, Bedlack R, Burns DK, Lutz MW, Siddique N, Siddique T, Roses AD, et al. Disease-modifying effects of an structural variant in a predominantly ALS cohort. Neurology. Genetics. 6: e470. PMID 32754644 DOI: 10.1212/Nxg.0000000000000470 |
0.376 |
|
| 2020 |
Theunissen F, Flynn LL, Anderton RS, Mastaglia F, Pytte J, Jiang L, Hodgetts S, Burns DK, Saunders A, Fletcher S, Wilton SD, Akkari PA. Structural Variants May Be a Source of Missing Heritability in sALS. Frontiers in Neuroscience. 14: 47. PMID 32082115 DOI: 10.3389/Fnins.2020.00047 |
0.344 |
|
| 2019 |
Burns DK, Chiang C, Welsh-Bohmer KA, Brannan SK, Culp M, O'Neil J, Runyan G, Harrigan P, Plassman BL, Lutz M, Lai E, Haneline S, Yarnall D, Yarbrough D, Metz C, ... ... Saunders AM, et al. The TOMMORROW study: Design of an Alzheimer's disease delay-of-onset clinical trial. Alzheimer's & Dementia (New York, N. Y.). 5: 661-670. PMID 31720367 DOI: 10.1016/J.Trci.2019.09.010 |
0.45 |
|
| 2019 |
Alexander R, Burns DK, Welsh-Bohmer KA, Burke JR, Chiang C, Culp M, Plassman BL, Wu J, Lutz MW, Rubens R, Evans R, Saunders AM, Ratti E. DT-02-02: TOMMORROW: RESULTS FROM A PHASE 3 TRIAL TO DELAY THE ONSET OF MCI DUE TO AD AND QUALIFY A GENETIC BIOMARKER ALGORITHM Alzheimer's & Dementia. 15: P1488-P1489. DOI: 10.1016/J.Jalz.2019.08.011 |
0.355 |
|
| 2018 |
Zietlow K, Charalambous L, Ng I, Gagrani S, Mihovilovic M, Luo S, Rock DL, Saunders A, Roses AD, Kirby Gottschalk W. Corrigendum to "The Biological Foundation of the Genetic Association of TOMM40 with Late-onset Alzheimer's disease" [Biochim. Biophys. Acta 1863/11 (2017) 2973-2986]. Biochimica Et Biophysica Acta. PMID 29395737 DOI: 10.1016/J.Bbadis.2018.01.017 |
0.438 |
|
| 2018 |
Lutz MW, Chiba-Falek O, Burns DK, Saunders AM. F2-03-01: Untangling The Genetic Complexity Of Late Onset Alzheimer'S Disease Alzheimers & Dementia. 14. DOI: 10.1016/J.Jalz.2018.06.2619 |
0.37 |
|
| 2018 |
Chiang C, Alexander R, Welsh-Bohmer KA, Plassman BL, Romero H, Hayden KM, Keefe RS, Atkins AS, Harrigan P, O'Neil J, Culp M, Walter R, Wu J, Randle L, Haneline S, ... ... Saunders AM, et al. P1-050: Adjudicating Mild Cognitive Impairment Due To Alzheimer'S Disease As A Novel Endpoint Event In The Tommorrow Study: A Delay-Of-Onset Phase 3 Clinical Trial Alzheimers & Dementia. 14. DOI: 10.1016/J.Jalz.2018.06.051 |
0.382 |
|
| 2017 |
Nishimura A, Nonomura H, Tanaka S, Yoshida M, Maruyama Y, Aritomi Y, Saunders AM, Burns DK, Lutz MW, Runyan G, Lai E, Budur K, Roses AD. Characterization of APOE and TOMM40 allele frequencies in the Japanese population. Alzheimer's & Dementia (New York, N. Y.). 3: 524-530. PMID 29124110 DOI: 10.1016/J.Trci.2017.07.003 |
0.475 |
|
| 2017 |
Zeitlow K, Charlambous L, Ng I, Gagrani S, Mihovilovic M, Luo S, Rock DL, Saunders A, Roses AD, Kirby Gottschalk W. The Biological Foundation of the Genetic Association of TOMM40 with Late-onset Alzheimer's disease. Biochimica Et Biophysica Acta. PMID 28768149 DOI: 10.1016/J.Bbadis.2017.07.031 |
0.335 |
|
| 2017 |
Yu L, Lutz MW, Wilson RS, Burns DK, Roses AD, Saunders AM, Yang J, Gaiteri C, De Jager PL, Barnes LL, Bennett DA. APOE ε4-TOMM40 '523 haplotypes and the risk of Alzheimer's disease in older Caucasian and African Americans. Plos One. 12: e0180356. PMID 28672022 DOI: 10.1371/Journal.Pone.0180356 |
0.454 |
|
| 2017 |
Yu L, Lutz MW, Farfel JM, Wilson RS, Burns DK, Saunders AM, De Jager PL, Barnes LL, Schneider JA, Bennett DA. Neuropathologic features of TOMM40 '523 variant on late-life cognitive decline. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. PMID 28624335 DOI: 10.1016/J.Jalz.2017.05.002 |
0.304 |
|
| 2017 |
Larsen PA, Lutz MW, Hunnicutt KE, Mihovilovic M, Saunders AM, Yoder AD, Roses AD. The Alu neurodegeneration hypothesis: A primate-specific mechanism for neuronal transcription noise, mitochondrial dysfunction, and manifestation of neurodegenerative disease. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. PMID 28242298 DOI: 10.1016/J.Jalz.2017.01.017 |
0.318 |
|
| 2017 |
Yu L, Lutz MW, Wilson RS, Burns DK, Roses AD, Saunders AM, Gaiteri C, De Jager PL, Barnes LL, Bennett DA. TOMM40'523 variant and cognitive decline in older persons with APOE ε3/3 genotype. Neurology. PMID 28108637 DOI: 10.1212/Wnl.0000000000003614 |
0.453 |
|
| 2016 |
Roses A, Sundseth S, Saunders A, Gottschalk W, Burns D, Lutz M. Understanding the genetics of APOE and TOMM40 and role of mitochondrial structure and function in clinical pharmacology of Alzheimer's disease. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. PMID 27154058 DOI: 10.1016/J.Jalz.2016.03.015 |
0.492 |
|
| 2016 |
Lutz MW, Sundseth SS, Burns DK, Saunders AM, Hayden KM, Burke JR, Welsh-Bohmer KA, Roses AD. A Genetics-based Biomarker Risk Algorithm for Predicting Risk of Alzheimer's Disease. Alzheimer's & Dementia : Translational Research & Clinical Interventions. 2: 30-44. PMID 27047990 DOI: 10.1016/J.Trci.2015.12.002 |
0.444 |
|
| 2016 |
Roses AD, Akkari PA, Chiba-Falek O, Lutz MW, Gottschalk WK, Saunders AM, Saul B, Sundseth S, Burns D. Structural variants can be more informative for disease diagnostics, prognostics and translation than current SNP mapping and exon sequencing. Expert Opinion On Drug Metabolism & Toxicology. PMID 26727306 DOI: 10.1517/17425255.2016.1133586 |
0.31 |
|
| 2016 |
Martenyi F, Welsh-Bohmer KA, Plassman BL, Harrigan P, Chiang C, O'Neil J, Runyan G, Culp M, Lutz MW, Lai E, Saunders AM, Haneline S, Yarnall D, Yarbrough D, Metz C, et al. Characterization Of The Screened Population For The Tommorrow Study: A Pharmacogenetics-Supported Clinical Trial To Delay The Onset Of Mild Cognitive Impairment Due To Alzheimer’S Disease Alzheimers & Dementia. 12: 1184. DOI: 10.1016/J.Jalz.2016.07.129 |
0.326 |
|
| 2016 |
Charalambous LT, Ng I, Mihovilovic M, Saunders AM, Roses AD, Gottschalk WK. Tomm40 Overexpression And Ppar-Gamma Agonists Protect Cells From Pathophysiological Stress Associated With Late Onset Alzheimer'S Disease Alzheimers & Dementia. 12: 1149. DOI: 10.1016/J.Jalz.2016.07.044 |
0.37 |
|
| 2016 |
Yu L, Lutz MW, Wilson RS, Burns DK, Roses AD, Saunders AM, Jager PLD, Barnes LL, Bennett DA. Tomm40 ‘523 Variant And Cognitive Decline In Community Based Older Persons With Apoe E3/3 Genotype Alzheimers & Dementia. 12. DOI: 10.1016/J.Jalz.2016.07.038 |
0.34 |
|
| 2016 |
Yu L, Lutz MW, Wilson RS, Burns DK, Roses AD, Saunders AM, Jager PLD, Barnes LL, Bennett DA. Apoe–Tomm40 ‘523 Haplotypes And The Risk Of Alzheimer’S Disease In Older Caucasian And African Americans Alzheimers & Dementia. 12: 1146. DOI: 10.1016/J.Jalz.2016.07.036 |
0.318 |
|
| 2015 |
Lyall DM, Muñoz Maniega S, Harris SE, Bastin ME, Murray C, Lutz MW, Saunders AM, Roses AD, Valdés Hernández MD, Royle NA, Starr JM, Porteous DJ, Deary IJ, Wardlaw JM. APOE/TOMM40 genetic loci, white matter hyperintensities, and cerebral microbleeds. International Journal of Stroke : Official Journal of the International Stroke Society. PMID 26310205 DOI: 10.1111/Ijs.12615 |
0.361 |
|
| 2015 |
Lutz MW, Soldan A, Selnes O, Roses AD, Saunders AM, Burns DK, Albert MS. P3-018: Tomm40/ApoE variation and age of onset of mild cognitive impairment and dementia in a prospective, longitudinal study Alzheimer's & Dementia. 11: P626-P627. DOI: 10.1016/J.Jalz.2015.06.884 |
0.381 |
|
| 2015 |
Budur K, Welsh-Bohmer K, Burns DK, Chiang C, O'Neil J, Runyan G, Culp M, Crenshaw DG, Lutz MW, Metz CA, Saunders AM, Yarbrough D, Yarnall D, Lai E, Brannan SK, et al. P2-083: Progress in the tommorrow study: A pharmacogenetics supported clinical trial to delay onset of mild cognitive impairment due to Alzheimer's disease with low-dose pioglitazone Alzheimer's & Dementia. 11: P515-P515. DOI: 10.1016/J.Jalz.2015.06.620 |
0.389 |
|
| 2014 |
Gottschalk WK, Lutz MW, He YT, Saunders AM, Burns DK, Roses AD, Chiba-Falek O. The Broad Impact of TOM40 on Neurodegenerative Diseases in Aging. Journal of Parkinson's Disease and Alzheimer's Disease. 1. PMID 25745640 DOI: 10.13188/2376-922X.1000003 |
0.351 |
|
| 2014 |
Roses AD, Lutz MW, Saunders AM, Goldgaber D, Saul R, Sundseth SS, Akkari PA, Roses SM, Gottschalk WK, Whitfield KE, Vostrov AA, Hauser MA, Allingham RR, Burns DK, Chiba-Falek O, et al. African-American TOMM40'523-APOE haplotypes are admixture of West African and Caucasian alleles. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. 10: 592-601.e2. PMID 25260913 DOI: 10.1016/J.Jalz.2014.06.009 |
0.414 |
|
| 2014 |
Lyall DM, Harris SE, Bastin ME, Muñoz Maniega S, Murray C, Lutz MW, Saunders AM, Roses AD, Valdés Hernández Mdel C, Royle NA, Starr JM, Porteous DJ, Wardlaw JM, Deary IJ. Are APOE ɛ genotype and TOMM40 poly-T repeat length associations with cognitive ageing mediated by brain white matter tract integrity? Translational Psychiatry. 4: e449. PMID 25247594 DOI: 10.1038/Tp.2014.89 |
0.4 |
|
| 2014 |
Greenbaum L, Springer RR, Lutz MW, Heymann A, Lubitz I, Cooper I, Kravitz E, Sano M, Roses AD, Silverman JM, Saunders AM, Beeri MS. The TOMM40 poly-T rs10524523 variant is associated with cognitive performance among non-demented elderly with type 2 diabetes. European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology. 24: 1492-9. PMID 25044051 DOI: 10.1016/J.Euroneuro.2014.06.002 |
0.389 |
|
| 2014 |
Roses AD, Saunders AM, Lutz MW, Zhang N, Hariri AR, Asin KE, Crenshaw DG, Budur K, Burns DK, Brannan SK. New applications of disease genetics and pharmacogenetics to drug development. Current Opinion in Pharmacology. 14: 81-9. PMID 24565016 DOI: 10.1016/J.Coph.2013.12.002 |
0.396 |
|
| 2014 |
Lyall DM, Harris SE, Bastin ME, Muñoz Maniega S, Murray C, Lutz MW, Saunders AM, Roses AD, Valdés Hernández Mdel C, Royle NA, Starr JM, Porteous DJ, Wardlaw JM, Deary IJ. Alzheimer's disease susceptibility genes APOE and TOMM40, and brain white matter integrity in the Lothian Birth Cohort 1936. Neurobiology of Aging. 35: 1513.e25-33. PMID 24508314 DOI: 10.1016/J.Neurobiolaging.2014.01.006 |
0.444 |
|
| 2014 |
Roses AD, Lutz MW, Saul R, Burns DK, Saunders AM, Goldgaber D, Sundseth SS, Akkari PA, Roses SM, Gottschalk WK, Whitfield KE, Vostrov AA, Hauser MA, Allingham RR, Chiba-Falek O, et al. P4-284: GENETIC RELATIONSHIP OF APOE AND TOMM40 HAPLOTYPES IN AFRICAN AMERICAN, WEST AFRICAN, AND CAUCASIAN COHORTS Alzheimer's & Dementia. 10: P888-P888. DOI: 10.1016/J.Jalz.2014.07.054 |
0.303 |
|
| 2014 |
Budur K, Welsh-Bohmer K, Burns D, Chiang C, O'Neil J, Runyan G, Cyganowski M, Crenshaw DG, Lutz MW, Metz C, Saunders A, Yarbrough D, Yarnall D, Lai E, Brannan S, et al. P4-073: A PHARMACOGENETICS-SUPPORTED CLINICAL TRIAL TO DELAY ONSET OF MILD COGNITIVE IMPAIRMENT DUE TO ALZHEIMER'S DISEASE USING LOW-DOSE PIOGLITAZONE: AN UPDATE ON THE TOMORROW STUDY Alzheimer's & Dementia. 10: P809-P810. DOI: 10.1016/J.Jalz.2014.05.1588 |
0.387 |
|
| 2014 |
Lutz MW, Saul R, Burns D, Saunders A, Roses A. P3-021: IDENTIFICATION AND CHARACTERIZATION OF POLYMORPHIC STRUCTURAL VARIANTS ASSOCIATED WITH ALZHEIMER'S DISEASE AND DISEASES OF AGING Alzheimer's & Dementia. 10: P635-P635. DOI: 10.1016/J.Jalz.2014.05.1108 |
0.361 |
|
| 2013 |
Lyall DM, Royle NA, Harris SE, Bastin ME, Maniega SM, Murray C, Lutz MW, Saunders AM, Roses AD, del Valdés Hernández MC, Starr JM, Porteous DJ, Wardlaw JM, Deary IJ. Alzheimer's disease susceptibility genes APOE and TOMM40, and hippocampal volumes in the Lothian birth cohort 1936. Plos One. 8: e80513. PMID 24260406 DOI: 10.1371/Journal.Pone.0080513 |
0.445 |
|
| 2013 |
Mastaglia FL, Rojana-udomsart A, James I, Needham M, Day TJ, Kiers L, Corbett JA, Saunders AM, Lutz MW, Roses AD. Polymorphism in the TOMM40 gene modifies the risk of developing sporadic inclusion body myositis and the age of onset of symptoms. Neuromuscular Disorders : Nmd. 23: 969-74. PMID 24103330 DOI: 10.1016/J.Nmd.2013.09.008 |
0.444 |
|
| 2013 |
Roses AD, Lutz MW, Crenshaw DG, Grossman I, Saunders AM, Gottschalk WK. TOMM40 and APOE: Requirements for replication studies of association with age of disease onset and enrichment of a clinical trial. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. 9: 132-6. PMID 23333464 DOI: 10.1016/J.Jalz.2012.10.009 |
0.479 |
|
| 2013 |
Crenshaw DG, Gottschalk WK, Lutz MW, Grossman I, Saunders AM, Burke JR, Welsh-Bohmer KA, Brannan SK, Burns DK, Roses AD. Using genetics to enable studies on the prevention of Alzheimer's disease. Clinical Pharmacology and Therapeutics. 93: 177-85. PMID 23249780 DOI: 10.1038/Clpt.2012.222 |
0.478 |
|
| 2013 |
Lutz M, Ogrinc F, Burns D, Saunders A, Roses A. P4-352: Performance of a genetics-based biomarker risk algorithm to support a clinical trial to delay onset of mild cognitive impairment due to Alzheimer's disease Alzheimer's & Dementia. 9: P860-P861. DOI: 10.1016/J.Jalz.2013.08.186 |
0.4 |
|
| 2012 |
Caselli RJ, Dueck AC, Huentelman MJ, Lutz MW, Saunders AM, Reiman EM, Roses AD. Longitudinal modeling of cognitive aging and the TOMM40 effect. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. 8: 490-5. PMID 23102119 DOI: 10.1016/J.Jalz.2011.11.006 |
0.42 |
|
| 2012 |
Hayden KM, McEvoy JM, Linnertz C, Attix D, Kuchibhatla M, Saunders AM, Lutz MW, Welsh-Bohmer KA, Roses AD, Chiba-Falek O. A homopolymer polymorphism in the TOMM40 gene contributes to cognitive performance in aging. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. 8: 381-8. PMID 22863908 DOI: 10.1016/J.Jalz.2011.10.005 |
0.447 |
|
| 2012 |
Linnertz C, Saunders AM, Lutz MW, Crenshaw DM, Grossman I, Burns DK, Whitfield KE, Hauser MA, McCarthy JJ, Ulmer M, Allingham R, Welsh-Bohmer KA, Roses AD, Chiba-Falek O. Characterization of the poly-T variant in the TOMM40 gene in diverse populations. Plos One. 7: e30994. PMID 22359560 DOI: 10.1371/Journal.Pone.0030994 |
0.38 |
|
| 2012 |
Roses AD, Welsh-Bohmer K, Burns D, Chiang C, Crenshaw DG, Lutz MW, Metz C, Saunders AM, Talbott S, Yarbrough D, Brannan S. P4-269: A pharmacogenetic-supported clinical trial to delay onset of mild cognitive impairment (MCI) due to Alzheimer's disease (AD) Alzheimer's & Dementia. 8: S753-S753. DOI: 10.1016/J.Jalz.2013.08.050 |
0.448 |
|
| 2012 |
Lutz M, Crenshaw D, Saunders A, Chiba-Falek O, Gottschalk K, Burns D, Grossman I, Roses A. P4-122: TOMM40-APOE regulatory haplotype and age of onset of late-onset Alzheimer's disease Alzheimer's & Dementia. 8: P674-P674. DOI: 10.1016/J.Jalz.2012.05.1825 |
0.464 |
|
| 2011 |
Johnson SC, La Rue A, Hermann BP, Xu G, Koscik RL, Jonaitis EM, Bendlin BB, Hogan KJ, Roses AD, Saunders AM, Lutz MW, Asthana S, Green RC, Sager MA. The effect of TOMM40 poly-T length on gray matter volume and cognition in middle-aged persons with APOE ε3/ε3 genotype. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. 7: 456-65. PMID 21784354 DOI: 10.1016/J.Jalz.2010.11.012 |
0.415 |
|
| 2011 |
Harrington C, Sawchak S, Chiang C, Davies J, Donovan C, Saunders AM, Irizarry M, Jeter B, Zvartau-Hind M, van Dyck CH, Gold M. Rosiglitazone does not improve cognition or global function when used as adjunctive therapy to AChE inhibitors in mild-to-moderate Alzheimer's disease: two phase 3 studies. Current Alzheimer Research. 8: 592-606. PMID 21592048 DOI: 10.2174/156720511796391935 |
0.388 |
|
| 2011 |
Roses AD, Crenshaw D, Saunders A. PPARgamma Agonists and Alzheimer's Disease: The Use of TOMM40 polyT Length Variations in Pharmacogenetic-Assisted Clinical Trial Designs Annual Review of Pharmacology and Toxicology. 52: 110301101444027. DOI: 10.1146/Annurev-Pharmtox-010510-100543 |
0.365 |
|
| 2011 |
Hayden K, Lutz M, Saunders A, Romero H, Burke J, Welsh-Bohmer K, Roses A. P1-235: TOMM40 “523” Genotype Affects Age of Alzheimer's Disease Onset Differentially by Race Alzheimer's & Dementia. 7: S186-S186. DOI: 10.1016/J.Jalz.2011.05.515 |
0.445 |
|
| 2010 |
Grossman I, Lutz MW, Crenshaw DG, Saunders AM, Burns DK, Roses AD. Alzheimer's disease: diagnostics, prognostics and the road to prevention. The Epma Journal. 1: 293-303. PMID 21124753 DOI: 10.1007/S13167-010-0024-3 |
0.463 |
|
| 2010 |
Gold M, Alderton C, Zvartau-Hind M, Egginton S, Saunders AM, Irizarry M, Craft S, Landreth G, Linnamägi U, Sawchak S. Rosiglitazone monotherapy in mild-to-moderate Alzheimer's disease: results from a randomized, double-blind, placebo-controlled phase III study. Dementia and Geriatric Cognitive Disorders. 30: 131-46. PMID 20733306 DOI: 10.1159/000318845 |
0.426 |
|
| 2010 |
Lutz MW, Crenshaw DG, Saunders AM, Roses AD. Genetic variation at a single locus and age of onset for Alzheimer's disease. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. 6: 125-31. PMID 20298972 DOI: 10.1016/J.Jalz.2010.01.011 |
0.458 |
|
| 2010 |
Roses AD, Lutz MW, Amrine-Madsen H, Saunders AM, Crenshaw DG, Sundseth SS, Huentelman MJ, Welsh-Bohmer KA, Reiman EM. A TOMM40 variable-length polymorphism predicts the age of late-onset Alzheimer's disease. The Pharmacogenomics Journal. 10: 375-84. PMID 20029386 DOI: 10.1038/Tpj.2009.69 |
0.427 |
|
| 2010 |
Sager MA, La Rue A, Johnson SC, Saunders AM, Roses AD, Koscik R, Jonaitis E, Lutz MW, Asthana S, Green RC, Hermann BP. P4-050: TOMM40 Variable Length Polymorphism is Associated With Memory Function in Asymptomatic Middle-aged Persons Alzheimer's & Dementia. 6: e35-e35. DOI: 10.1016/J.Jalz.2010.08.110 |
0.347 |
|
| 2010 |
Johnson SC, La Rue A, Hermann BP, Xu G, Koscik RL, Jonaitas EM, Bendlin BB, Roses AD, Saunders AM, Lutz MW, Asthana S, Green RC, Sager MA. O4-03-04: Tomm40 is Associated with Gray Matter Volume in Middle-aged Persons with Apoe ε3/ε3 Genotype Alzheimer's & Dementia. 6: e16-e16. DOI: 10.1016/J.Jalz.2010.08.049 |
0.316 |
|
| 2010 |
Caselli RJ, Saunders A, Lutz M, Huentelman M, Reiman E, Roses A. P1-096: TOMM40, APOE, and age of onset of Alzheimer's disease Alzheimer's & Dementia. 6: S202-S202. DOI: 10.1016/J.Jalz.2010.05.644 |
0.451 |
|
| 2009 |
Harrington C, Sawchak S, Chiang C, Davies J, Saunders A, Irizarry M, Zvartau-Hind M, Dyck Cv, Gold M. Effects Of Rosiglitazone-extended Release As Adjunctive Therapy To Acetylcholinesterase Inhibitors Over 48 Weeks On Cognition In Apoe4-stratified Subjects With Mild-to-moderate Alzheimer'S Disease Alzheimers & Dementia. 5. DOI: 10.1016/J.Jalz.2009.07.079 |
0.374 |
|
| 2009 |
Gold M, Alderton C, Zvartau-Hind M, Ritchie S, Saunders A, Craft S, Landreth G, Linnamägi Ü, Sawchak S. Effects of rosiglitazone as monotherapy in APOE4-stratified subjects with mild-to-moderate Alzheimer's disease Alzheimers & Dementia. 5: 86. DOI: 10.1016/J.Jalz.2009.05.219 |
0.423 |
|
| 2009 |
Alderton C, Zvartau-Hind M, Ritchie S, Saunders A, Craft S, Landreth G, Linnamägi Ü, Sawchak S, Gold M. Secondary endpoint and responder analyses in a study of rosiglitazone XR in APOE4-stratified subjects with mild-to-moderate Alzheimer's disease Alzheimers & Dementia. 5: 254. DOI: 10.1016/J.Jalz.2009.04.271 |
0.426 |
|
| 2009 |
Zvartau-Hind M, Alderton C, Ritchie S, Saunders A, Irizarry M, Craft S, Landreth G, Linnamägi Ü, Sawchak S, Gold M. Safety and tolerability of rosiglitazone XR in a randomised, placebo-controlled study in APOE4-stratified subjects with mild-to-moderate Alzheimer's disease Alzheimers & Dementia. 5: 248. DOI: 10.1016/J.Jalz.2009.04.252 |
0.375 |
|
| 2008 |
Akuffo EL, Davis JB, Fox SM, Gloger IS, Hosford D, Kinsey EE, Jones NA, Nock CM, Roses AD, Saunders AM, Skehel JM, Smith MA, Cutler P. The discovery and early validation of novel plasma biomarkers in mild-to-moderate Alzheimer's disease patients responding to treatment with rosiglitazone. Biomarkers : Biochemical Indicators of Exposure, Response, and Susceptibility to Chemicals. 13: 618-36. PMID 18830857 DOI: 10.1080/13547500802445199 |
0.404 |
|
| 2008 |
Cogswell JP, Ward J, Taylor IA, Waters M, Shi Y, Cannon B, Kelnar K, Kemppainen J, Brown D, Chen C, Prinjha RK, Richardson JC, Saunders AM, Roses AD, Richards CA. Identification of miRNA changes in Alzheimer's disease brain and CSF yields putative biomarkers and insights into disease pathways. Journal of Alzheimer's Disease : Jad. 14: 27-41. PMID 18525125 DOI: 10.3233/Jad-2008-14103 |
0.373 |
|
| 2008 |
Brodbeck J, Balestra ME, Saunders AM, Roses AD, Mahley RW, Huang Y. Rosiglitazone increases dendritic spine density and rescues spine loss caused by apolipoprotein E4 in primary cortical neurons. Proceedings of the National Academy of Sciences of the United States of America. 105: 1343-6. PMID 18212130 DOI: 10.1073/Pnas.0709906104 |
0.407 |
|
| 2008 |
Li H, Wetten S, Li L, St Jean PL, Upmanyu R, Surh L, Hosford D, Barnes MR, Briley JD, Borrie M, Coletta N, Delisle R, Dhalla D, Ehm MG, Feldman HH, ... ... Saunders A, et al. Candidate single-nucleotide polymorphisms from a genomewide association study of Alzheimer disease. Archives of Neurology. 65: 45-53. PMID 17998437 DOI: 10.1001/Archneurol.2007.3 |
0.485 |
|
| 2008 |
Richardson JC, Cogswell JP, Ward J, Taylor IA, Waters M, Shi Y, Cannon B, Kelnar K, Kemppainen J, Brown D, Chen C, Prinjha RK, Saunders AM, Roses AD, Richards CA. O3-02-07: Identification of miRNA changes in Alzheimer's disease brain and CSF yields putative biomarkers and insights into disease pathways Alzheimers & Dementia. 4. DOI: 10.1016/J.Jalz.2008.05.420 |
0.333 |
|
| 2007 |
Chen K, Reiman EM, Alexander GE, Caselli RJ, Gerkin R, Bandy D, Domb A, Osborne D, Fox N, Crum WR, Saunders AM, Hardy J. Correlations between apolipoprotein E epsilon4 gene dose and whole brain atrophy rates. The American Journal of Psychiatry. 164: 916-21. PMID 17541051 DOI: 10.1176/Ajp.2007.164.6.916 |
0.441 |
|
| 2007 |
Roses AD, Saunders AM, Huang Y, Strum J, Weisgraber KH, Mahley RW. Complex disease-associated pharmacogenetics: drug efficacy, drug safety, and confirmation of a pathogenetic hypothesis (Alzheimer's disease). The Pharmacogenomics Journal. 7: 10-28. PMID 16770341 DOI: 10.1038/Sj.Tpj.6500397 |
0.368 |
|
| 2006 |
Roses AD, Saunders AM. Perspective on a pathogenesis and treatment of Alzheimer's disease. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. 2: 59-70. PMID 19595857 DOI: 10.1016/J.Jalz.2005.12.001 |
0.402 |
|
| 2006 |
Risner ME, Saunders AM, Altman JF, Ormandy GC, Craft S, Foley IM, Zvartau-Hind ME, Hosford DA, Roses AD. Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer's disease. The Pharmacogenomics Journal. 6: 246-54. PMID 16446752 DOI: 10.1038/Sj.Tpj.6500369 |
0.448 |
|
| 2006 |
Halford J, Mazeika G, Slifer S, Speer M, Saunders AM, Strittmatter WJ, Morgenlander JC. APOE2 allele increased in tardive dyskinesia. Movement Disorders : Official Journal of the Movement Disorder Society. 21: 540-2. PMID 16261623 DOI: 10.1002/Mds.20768 |
0.382 |
|
| 2006 |
Hosford DA, Altman JF, Saunders AM, Risner ME, Zvartau-Hind ME, Ormandy GC, Roses AD. O4-03-07: Efficacy of rosiglitazone (RSG) in patients with mild to moderate Alzheimer's disease (AD) Alzheimer's & Dementia. 2: S81-S81. DOI: 10.1016/J.Jalz.2006.05.315 |
0.427 |
|
| 2006 |
Zvartau-Hind ME, Hosford DA, Saunders AM, Risner ME, Ormandy GC, Craft S, Altman JF, Foley I, Roses AD. P2-397: Safety and tolerability of rosiglitazone (RSG) in patients with mild to moderate Alzheimer's disease (AD) Alzheimer's & Dementia. 2: S362-S363. DOI: 10.1016/J.Jalz.2006.05.1236 |
0.437 |
|
| 2005 |
Reiman EM, Chen K, Alexander GE, Caselli RJ, Bandy D, Osborne D, Saunders AM, Hardy J. Correlations between apolipoprotein E epsilon4 gene dose and brain-imaging measurements of regional hypometabolism. Proceedings of the National Academy of Sciences of the United States of America. 102: 8299-302. PMID 15932949 DOI: 10.1073/Pnas.0500579102 |
0.478 |
|
| 2004 |
Li YJ, Pericak-Vance MA, Haines JL, Siddique N, McKenna-Yasek D, Hung WY, Sapp P, Allen CI, Chen W, Hosler B, Saunders AM, Dellefave LM, Brown RH, Siddique T. Apolipoprotein E is associated with age at onset of amyotrophic lateral sclerosis. Neurogenetics. 5: 209-13. PMID 15657798 DOI: 10.1007/S10048-004-0193-0 |
0.44 |
|
| 2004 |
Nicodemus KK, Stenger JE, Schmechel DE, Welsh-Bohmer KA, Saunders AM, Roses AD, Gilbert JR, Vance JM, Haines JL, Pericak-Vance MA, Martin ER. Comprehensive association analysis of APOE regulatory region polymorphisms in Alzheimer disease. Neurogenetics. 5: 201-8. PMID 15455263 DOI: 10.1007/S10048-004-0189-9 |
0.48 |
|
| 2004 |
van der Walt JM, Dementieva YA, Martin ER, Scott WK, Nicodemus KK, Kroner CC, Welsh-Bohmer KA, Saunders AM, Roses AD, Small GW, Schmechel DE, Murali Doraiswamy P, Gilbert JR, Haines JL, Vance JM, et al. Analysis of European mitochondrial haplogroups with Alzheimer disease risk. Neuroscience Letters. 365: 28-32. PMID 15234467 DOI: 10.1016/J.Neulet.2004.04.051 |
0.458 |
|
| 2004 |
Reiman EM, Chen K, Alexander GE, Caselli RJ, Bandy D, Osborne D, Saunders AM, Hardy J. Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's dementia. Proceedings of the National Academy of Sciences of the United States of America. 101: 284-9. PMID 14688411 DOI: 10.1073/Pnas.2635903100 |
0.445 |
|
| 2003 |
Li YJ, Oliveira SA, Xu P, Martin ER, Stenger JE, Scherzer CR, Hauser MA, Scott WK, Small GW, Nance MA, Watts RL, Hubble JP, Koller WC, Pahwa R, Stern MB, ... ... Saunders AM, et al. Glutathione S-transferase omega-1 modifies age-at-onset of Alzheimer disease and Parkinson disease. Human Molecular Genetics. 12: 3259-67. PMID 14570706 DOI: 10.1093/Hmg/Ddg357 |
0.449 |
|
| 2003 |
Scott WK, Hauser ER, Schmechel DE, Welsh-Bohmer KA, Small GW, Roses AD, Saunders AM, Gilbert JR, Vance JM, Haines JL, Pericak-Vance MA. Ordered-subsets linkage analysis detects novel Alzheimer disease loci on chromosomes 2q34 and 15q22. American Journal of Human Genetics. 73: 1041-51. PMID 14564669 DOI: 10.1086/379083 |
0.387 |
|
| 2003 |
Oliveira SA, Martin ER, Scott WK, Nicodemus KK, Small GW, Schmechel DE, Doraiswamy PM, Roses AD, Saunders AM, Gilbert JR, Haines JL, Vance JM, Pericak-Vance MA. The Q7R Saitohin gene polymorphism is not associated with Alzheimer disease. Neuroscience Letters. 347: 143-6. PMID 12875906 DOI: 10.1016/S0304-3940(03)00670-0 |
0.478 |
|
| 2003 |
DeKroon RM, Mihovilovic M, Goodger ZV, Robinette JB, Sullivan PM, Saunders AM, Strittmatter WJ. ApoE genotype-specific inhibition of apoptosis. Journal of Lipid Research. 44: 1566-73. PMID 12754278 DOI: 10.1194/Jlr.M300097-Jlr200 |
0.32 |
|
| 2003 |
Bedlack RS, Edelman D, Gibbs JW, Kelling D, Strittmatter W, Saunders AM, Morgenlander J. APOE genotype is a risk factor for neuropathy severity in diabetic patients. Neurology. 60: 1022-4. PMID 12654974 DOI: 10.1212/01.Wnl.0000056689.50682.94 |
0.319 |
|
| 2002 |
Schmidt S, Klaver C, Saunders A, Postel E, De La Paz M, Agarwal A, Small K, Udar N, Ong J, Chalukya M, Nesburn A, Kenney C, Domurath R, Hogan M, Mah T, et al. A pooled case-control study of the apolipoprotein E (APOE) gene in age-related maculopathy. Ophthalmic Genetics. 23: 209-23. PMID 12567264 DOI: 10.1076/Opge.23.4.209.13883 |
0.411 |
|
| 2002 |
Colton CA, Brown CM, Cook D, Needham LK, Xu Q, Czapiga M, Saunders AM, Schmechel DE, Rasheed K, Vitek MP. APOE and the regulation of microglial nitric oxide production: a link between genetic risk and oxidative stress. Neurobiology of Aging. 23: 777-85. PMID 12392781 DOI: 10.1016/S0197-4580(02)00016-7 |
0.36 |
|
| 2002 |
Fillenbaum GG, Blazer DG, Burchett BM, Saunders AM, Taylor DH. Apolipoprotein E epsilon4 and risk of mortality in African American and white older community residents. The Gerontologist. 42: 381-6. PMID 12040140 DOI: 10.1093/Geront/42.3.381 |
0.337 |
|
| 2002 |
Caselli RJ, Hentz JG, Osborne D, Graff-Radford NR, Barbieri CJ, Alexander GE, Hall GR, Reiman EM, Hardy J, Saunders AM. Apolipoprotein E and intellectual achievement. Journal of the American Geriatrics Society. 50: 49-54. PMID 12028246 DOI: 10.1046/J.1532-5415.2002.50007.X |
0.341 |
|
| 2002 |
Li YJ, Scott WK, Hedges DJ, Zhang F, Gaskell PC, Nance MA, Watts RL, Hubble JP, Koller WC, Pahwa R, Stern MB, Hiner BC, Jankovic J, Allen FA, Goetz CG, ... ... Saunders AM, et al. Age at onset in two common neurodegenerative diseases is genetically controlled. American Journal of Human Genetics. 70: 985-93. PMID 11875758 DOI: 10.1086/339815 |
0.411 |
|
| 2002 |
Schmidt S, Barcellos LF, DeSombre K, Rimmler JB, Lincoln RR, Bucher P, Saunders AM, Lai E, Martin ER, Vance JM, Oksenberg JR, Hauser SL, Pericak-Vance MA, Haines JL. Association of polymorphisms in the apolipoprotein E region with susceptibility to and progression of multiple sclerosis. American Journal of Human Genetics. 70: 708-17. PMID 11836653 DOI: 10.1086/339269 |
0.394 |
|
| 2001 |
Rosenberg CK, Cummings TJ, Saunders AM, Widico C, McIntyre LM, Hulette CM. Dementia with Lewy bodies and Alzheimer's disease. Acta Neuropathologica. 102: 621-6. PMID 11761723 DOI: 10.1007/S004010100415 |
0.466 |
|
| 2001 |
Fillenbaum GG, Landerman LR, Blazer DG, Saunders AM, Harris TB, Launer LJ. The relationship of APOE genotype to cognitive functioning in older African-American and Caucasian community residents. Journal of the American Geriatrics Society. 49: 1148-55. PMID 11559372 DOI: 10.1046/J.1532-5415.2001.49230.X |
0.348 |
|
| 2001 |
Caselli RJ, Osborne D, Reiman EM, Hentz JG, Barbieri CJ, Saunders AM, Hardy J, Graff-Radford NR, Hall GR, Alexander GE. Preclinical cognitive decline in late middle-aged asymptomatic apolipoprotein E-e4/4 homozygotes: a replication study. Journal of the Neurological Sciences. 189: 93-8. PMID 11535238 DOI: 10.1016/S0022-510X(01)00577-9 |
0.362 |
|
| 2001 |
Saunders AM. Gene identification in Alzheimer's disease. Pharmacogenomics. 2: 239-49. PMID 11535112 DOI: 10.1517/14622416.2.3.239 |
0.435 |
|
| 2001 |
Newman MF, Laskowitz DT, White WD, Kirchner JL, Grocott HP, Stafford-Smith M, Sketch MH, Jones RH, Reves JG, Saunders AM. Apolipoprotein E polymorphisms and age at first coronary artery bypass graft. Anesthesia and Analgesia. 92: 824-9. PMID 11273909 DOI: 10.1097/00000539-200104000-00006 |
0.363 |
|
| 2000 |
Pericak-Vance MA, Grubber J, Bailey LR, Hedges D, West S, Santoro L, Kemmerer B, Hall JL, Saunders AM, Roses AD, Small GW, Scott WK, Conneally PM, Vance JM, Haines JL. Identification of novel genes in late-onset Alzheimer's disease. Experimental Gerontology. 35: 1343-52. PMID 11113612 DOI: 10.1016/S0531-5565(00)00196-0 |
0.467 |
|
| 2000 |
Kardaun JW, White L, Resnick HE, Petrovitch H, Marcovina SM, Saunders AM, Foley DJ, Havlik RJ. Genotypes and phenotypes for apolipoprotein E and Alzheimer disease in the Honolulu-Asia aging study. Clinical Chemistry. 46: 1548-54. PMID 11017931 DOI: 10.1093/Clinchem/46.10.1548 |
0.491 |
|
| 2000 |
Saunders AM. Apolipoprotein E and Alzheimer disease: an update on genetic and functional analyses. Journal of Neuropathology and Experimental Neurology. 59: 751-8. PMID 11005255 DOI: 10.1093/Jnen/59.9.751 |
0.524 |
|
| 2000 |
Rosenberg CK, Pericak-Vance MA, Saunders AM, Gilbert JR, Gaskell PC, Hulette CM. Lewy body and Alzheimer pathology in a family with the amyloid-beta precursor protein APP717 gene mutation. Acta Neuropathologica. 100: 145-52. PMID 10963361 DOI: 10.1007/S004019900155 |
0.418 |
|
| 2000 |
Bookheimer SY, Strojwas MH, Cohen MS, Saunders AM, Pericak-Vance MA, Mazziotta JC, Small GW. Patterns of brain activation in people at risk for Alzheimer's disease. The New England Journal of Medicine. 343: 450-6. PMID 10944562 DOI: 10.1056/Nejm200008173430701 |
0.43 |
|
| 2000 |
Chew ST, Newman MF, White WD, Conlon PJ, Saunders AM, Strittmatter WJ, Landolfo K, Grocott HP, Stafford-Smith M. Preliminary report on the association of apolipoprotein E polymorphisms, with postoperative peak serum creatinine concentrations in cardiac surgical patients. Anesthesiology. 93: 325-31. PMID 10910477 DOI: 10.1097/00000542-200008000-00008 |
0.318 |
|
| 2000 |
Saunders AM, Trowers MK, Shimkets RA, Blakemore S, Crowther DJ, Mansfield TA, Wallace DM, Strittmatter WJ, Roses AD. The role of apolipoprotein E in Alzheimer's disease: pharmacogenomic target selection. Biochimica Et Biophysica Acta. 1502: 85-94. PMID 10899434 DOI: 10.1016/S0925-4439(00)00035-1 |
0.52 |
|
| 2000 |
Small GW, Ercoli LM, Silverman DH, Huang SC, Komo S, Bookheimer SY, Lavretsky H, Miller K, Siddarth P, Rasgon NL, Mazziotta JC, Saxena S, Wu HM, Mega MS, Cummings JL, ... Saunders AM, et al. Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer's disease. Proceedings of the National Academy of Sciences of the United States of America. 97: 6037-42. PMID 10811879 DOI: 10.1073/Pnas.090106797 |
0.417 |
|
| 2000 |
Riley KP, Snowdon DA, Saunders AM, Roses AD, Mortimer JA, Nanayakkara N. Cognitive function and apolipoprotein E in very old adults: findings from the Nun Study. The Journals of Gerontology. Series B, Psychological Sciences and Social Sciences. 55: S69-75. PMID 10794191 DOI: 10.1093/Geronb/55.2.S69 |
0.402 |
|
| 2000 |
Havlik RJ, Izmirlian G, Petrovitch H, Ross GW, Masaki K, Curb JD, Saunders AM, Foley DJ, Brock D, Launer LJ, White L. APOE-epsilon4 predicts incident AD in Japanese-American men: the honolulu-asia aging study. Neurology. 54: 1526-9. PMID 10751272 DOI: 10.1212/Wnl.54.7.1526 |
0.424 |
|
| 2000 |
Scott WK, Grubber JM, Conneally PM, Small GW, Hulette CM, Rosenberg CK, Saunders AM, Roses AD, Haines JL, Pericak-Vance MA. Fine mapping of the chromosome 12 late-onset Alzheimer disease locus: potential genetic and phenotypic heterogeneity. American Journal of Human Genetics. 66: 922-32. PMID 10712207 DOI: 10.1086/302828 |
0.445 |
|
| 2000 |
Martin ER, Gilbert JR, Lai EH, Riley J, Rogala AR, Slotterbeck BD, Sipe CA, Grubber JM, Warren LL, Conneally PM, Saunders AM, Schmechel DE, Purvis I, Pericak-Vance MA, Roses AD, et al. Analysis of association at single nucleotide polymorphisms in the APOE region. Genomics. 63: 7-12. PMID 10662539 DOI: 10.1006/Geno.1999.6057 |
0.383 |
|
| 2000 |
Hulette CM, Pannell C, Ervin JF, Rosenberg CK, Saunders AM, Strittmatter WJ, Schmechel DE. Vascular abnormalities in APOE4,4 and APOE3,3 Alzheimer's disease Neurobiology of Aging. 21: 271. DOI: 10.1016/S0197-4580(00)83173-5 |
0.417 |
|
| 1999 |
Small GW, Scott WK, Komo S, Yamaoka LH, Farrer LA, Auerbach SH, Saunders AM, Roses AD, Haines JL, Pericak-Vance MA. No association between the HLA-A2 allele and Alzheimer disease. Neurogenetics. 2: 177-82. PMID 10541592 DOI: 10.1007/S100480050080 |
0.403 |
|
| 1999 |
Grubber JM, Saunders AM, Crane-Gatherum AR, Scott WK, Martin ER, Haynes CS, Conneally PM, Small GW, Roses AD, Haines JL, Pericak-Vance MA. Analysis of association between Alzheimer disease and the K variant of butyrylcholinesterase (BCHE-K). Neuroscience Letters. 269: 115-9. PMID 10430518 DOI: 10.1016/S0304-3940(99)00426-7 |
0.39 |
|
| 1999 |
Small GW, Chen ST, Komo S, Ercoli L, Bookheimer S, Miller K, Lavretsky H, Saxena S, Kaplan A, Dorsey D, Scott WK, Saunders AM, Haines JL, Roses AD, Pericak-Vance MA. Memory self-appraisal in middle-aged and older adults with the apolipoprotein E-4 allele. The American Journal of Psychiatry. 156: 1035-8. PMID 10401448 DOI: 10.1176/Ajp.156.7.1035 |
0.348 |
|
| 1999 |
Rogaeva EA, Premkumar S, Grubber J, Serneels L, Scott WK, Kawarai T, Song Y, Hill DL, Abou-Donia SM, Martin ER, Vance JJ, Yu G, Orlacchio A, Pei Y, Nishimura M, ... ... Saunders AM, et al. An alpha-2-macroglobulin insertion-deletion polymorphism in Alzheimer disease. Nature Genetics. 22: 19-22. PMID 10319855 DOI: 10.1038/8729 |
0.468 |
|
| 1999 |
Newman MF, Laskowitz DT, Saunders AM, Grigore AM, Grocott HP. Genetic Predictors of Perioperative Neurologic and Neuropsychological Injury and Recovery Seminars in Cardiothoracic and Vascular Anesthesia. 3: 34-46. DOI: 10.1177/108925329900300107 |
0.346 |
|
| 1999 |
Newman MF, Grigore AM, White WD, Laskowitz DT, Saunders AM, Grocott HP, Stafford-Smith M, Reves J. Apolipoprotein E Polymorphism And Age Of Presentation For Coronary Revascularization Anesthesia & Analgesia. 88. DOI: 10.1097/00000539-199904001-00084 |
0.311 |
|
| 1998 |
Siddique T, Pericak-Vance MA, Caliendo J, Hong ST, Hung WY, Kaplan J, McKenna-Yasek D, Rimmler JB, Sapp P, Saunders AM, Scott WK, Siddique N, Haines JL, Brown RH. Lack of association between apolipoprotein E genotype and sporadic amyotrophic lateral sclerosis. Neurogenetics. 1: 213-6. PMID 10737125 DOI: 10.1007/S100480050031 |
0.426 |
|
| 1998 |
Scott WK, Yamaoka LH, Bass MP, Gaskell PC, Conneally PM, Small GW, Farrer LA, Auerbach SA, Saunders AM, Roses AD, Haines JL, Pericak-Vance MA. No genetic association between the LRP receptor and sporadic or late-onset familial Alzheimer disease. Neurogenetics. 1: 179-83. PMID 10737120 DOI: 10.1007/S100480050026 |
0.489 |
|
| 1998 |
Einstein G, Patel V, Bautista P, Kenna M, Melone L, Fader R, Karson K, Mann S, Saunders AM, Hulette C, Mash D, Roses AD, Schmechel DE. Intraneuronal ApoE in human visual cortical areas reflects the staging of Alzheimer disease pathology. Journal of Neuropathology and Experimental Neurology. 57: 1190-201. PMID 9862642 DOI: 10.1097/00005072-199812000-00011 |
0.471 |
|
| 1998 |
Hulette CM, Welsh-Bohmer KA, Murray MG, Saunders AM, Mash DC, McIntyre LM. Neuropathological and neuropsychological changes in "normal" aging: evidence for preclinical Alzheimer disease in cognitively normal individuals. Journal of Neuropathology and Experimental Neurology. 57: 1168-74. PMID 9862640 DOI: 10.1097/00005072-199812000-00009 |
0.457 |
|
| 1998 |
Williams KR, Saunders AM, Roses AD, Armati PJ. Uptake and internalization of exogenous apolipoprotein E3 by cultured human central nervous system neurons. Neurobiology of Disease. 5: 271-9. PMID 9848097 DOI: 10.1006/Nbdi.1998.0198 |
0.381 |
|
| 1998 |
Farrer LA, Abraham CR, Haines JL, Rogaeva EA, Song Y, McGraw WT, Brindle N, Premkumar S, Scott WK, Yamaoka LH, Saunders AM, Roses AD, Auerbach SA, Sorbi S, Duara R, et al. Association between bleomycin hydrolase and Alzheimer's disease in caucasians. Annals of Neurology. 44: 808-11. PMID 9818937 DOI: 10.1002/Ana.410440515 |
0.503 |
|
| 1998 |
Bass MP, Yamaoka LH, Scott WK, Gaskell PC, Welsh-Bohmer KA, Roses AD, Saunders AM, Haines JL, Pericak-Vance MA. No association of alpha1-antichymotrypsin flanking region polymorphism and Alzheimer disease risk in early- and late-onset Alzheimer disease patients. Neuroscience Letters. 250: 79-82. PMID 9697923 DOI: 10.1016/S0304-3940(98)00398-X |
0.507 |
|
| 1998 |
Pericak-Vance MA, Bass ML, Yamaoka LH, Gaskell PC, Scott WK, Terwedow HA, Menold MM, Conneally PM, Small GW, Saunders AM, Roses AD, Haines JL. Complete genomic screen in late-onset familial Alzheimer's disease. Neurobiology of Aging. 19: S39-42. PMID 9562466 DOI: 10.1016/S0197-4580(98)00037-2 |
0.416 |
|
| 1998 |
Breitner JC, Jarvik GP, Plassman BL, Saunders AM, Welsh KA. Risk of Alzheimer disease with the epsilon4 allele for apolipoprotein E in a population-based study of men aged 62-73 years. Alzheimer Disease and Associated Disorders. 12: 40-4. PMID 9539409 DOI: 10.1097/00002093-199803000-00006 |
0.491 |
|
| 1998 |
Sheng H, Laskowitz DT, Bennett E, Schmechel DE, Bart RD, Saunders AM, Pearlstein RD, Roses AD, Warner DS. Apolipoprotein E isoform-specific differences in outcome from focal ischemia in transgenic mice. Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism. 18: 361-6. PMID 9538900 DOI: 10.1097/00004647-199804000-00003 |
0.334 |
|
| 1998 |
Berg L, McKeel DW, Miller JP, Storandt M, Rubin EH, Morris JC, Baty J, Coats M, Norton J, Goate AM, Price JL, Gearing M, Mirra SS, Saunders AM. Clinicopathologic studies in cognitively healthy aging and Alzheimer's disease: relation of histologic markers to dementia severity, age, sex, and apolipoprotein E genotype. Archives of Neurology. 55: 326-35. PMID 9520006 DOI: 10.1001/Archneur.55.3.326 |
0.499 |
|
| 1998 |
Mayeux R, Saunders AM, Shea S, Mirra S, Evans D, Roses AD, Hyman BT, Crain B, Tang MX, Phelps CH. Utility of the apolipoprotein E genotype in the diagnosis of Alzheimer's disease. Alzheimer's Disease Centers Consortium on Apolipoprotein E and Alzheimer's Disease. The New England Journal of Medicine. 338: 506-11. PMID 9468467 DOI: 10.1056/Nejm199802193380804 |
0.478 |
|
| 1997 |
Roses AD, Saunders AM. Apolipoprotein E genotyping as a diagnostic adjunct for Alzheimer's disease. International Psychogeriatrics / Ipa. 9: 277-88; discussion 3. PMID 9447448 DOI: 10.1017/S1041610297005012 |
0.498 |
|
| 1997 |
Pericak-Vance MA, Bass MP, Yamaoka LH, Gaskell PC, Scott WK, Terwedow HA, Menold MM, Conneally PM, Small GW, Vance JM, Saunders AM, Roses AD, Haines JL. Complete genomic screen in late-onset familial Alzheimer disease. Evidence for a new locus on chromosome 12. Jama. 278: 1237-41. PMID 9333264 DOI: 10.1001/Jama.1997.03550150041033 |
0.442 |
|
| 1997 |
Roses AD, Saunders AM. ApoE, Alzheimer's disease, and recovery from brain stress. Annals of the New York Academy of Sciences. 826: 200-12. PMID 9329691 DOI: 10.1111/J.1749-6632.1997.Tb48471.X |
0.519 |
|
| 1997 |
Tardiff BE, Newman MF, Saunders AM, Strittmatter WJ, Blumenthal JA, White WD, Croughwell ND, Davis RD, Roses AD, Reves JG. Preliminary report of a genetic basis for cognitive decline after cardiac operations. The Neurologic Outcome Research Group of the Duke Heart Center. The Annals of Thoracic Surgery. 64: 715-20. PMID 9307463 DOI: 10.1016/S0003-4975(97)00757-1 |
0.343 |
|
| 1997 |
Scott WK, Saunders AM, Gaskell PC, Locke PA, Growdon JH, Farrer LA, Auerbach SA, Roses AD, Haines JL, Pericak-Vance MA. Apolipoprotein E epsilon2 does not increase risk of early-onset sporadic Alzheimer's disease. Annals of Neurology. 42: 376-8. PMID 9307262 DOI: 10.1002/Ana.410420317 |
0.497 |
|
| 1997 |
Welsh-Bohmer KA, Gearing M, Saunders AM, Roses AD, Mirra S. Apolipoprotein E genotypes in a neuropathological series from the Consortium to Establish a Registry for Alzheimer's Disease. Annals of Neurology. 42: 319-25. PMID 9307253 DOI: 10.1002/Ana.410420308 |
0.486 |
|
| 1997 |
Williams KR, Pye V, Saunders AM, Roses AD, Armati PJ. Apolipoprotein E uptake and low-density lipoprotein receptor-related protein expression by the NTera2/D1 cell line: a cell culture model of relevance for late-onset Alzheimer's disease. Neurobiology of Disease. 4: 58-67. PMID 9258912 DOI: 10.1006/Nbdi.1997.0131 |
0.378 |
|
| 1997 |
Alexander GE, Saunders AM, Szczepanik J, Strassburger TL, Pietrini P, Dani A, Furey ML, Mentis MJ, Roses AD, Rapoport SI, Schapiro MB. Relation of age and apolipoprotein E to cognitive function in Down syndrome adults. Neuroreport. 8: 1835-40. PMID 9223061 DOI: 10.1097/00001756-199705260-00009 |
0.458 |
|
| 1997 |
Scott WK, Yamaoka LH, Locke PA, Rosi BL, Gaskell PC, Saunders AM, Conneally PM, Small GW, Farrer LA, Growdon JH, Roses AD, Pericak-Vance MA, Haines JL. No association or linkage between an intronic polymorphism of presenilin-1 and sporadic or late-onset familial Alzheimer disease. Genetic Epidemiology. 14: 307-15. PMID 9181359 DOI: 10.1002/(Sici)1098-2272(1997)14:3<307::Aid-Gepi8>3.0.Co;2-1 |
0.485 |
|
| 1997 |
Steffens DC, Plassman BL, Helms MJ, Welsh-Bohmer KA, Saunders AM, Breitner JC. A twin study of late-onset depression and apolipoprotein E epsilon 4 as risk factors for Alzheimer's disease. Biological Psychiatry. 41: 851-6. PMID 9099411 DOI: 10.1016/S0006-3223(96)00247-8 |
0.415 |
|
| 1997 |
Small GW, Noble EP, Matsuyama SS, Jarvik LF, Komo S, Kaplan A, Ritchie T, Pritchard ML, Saunders AM, Conneally PM, Roses AD, Haines JL, Pericak-Vance MA. D2 dopamine receptor A1 allele in Alzheimer disease and aging. Archives of Neurology. 54: 281-5. PMID 9074397 DOI: 10.1001/Archneur.1997.00550150041014 |
0.393 |
|
| 1997 |
Lippa CF, Smith TW, Saunders AM, Hulette C, Pulaski-Salo D, Roses AD. Apolipoprotein E-epsilon 2 and Alzheimer's disease: genotype influences pathologic phenotype. Neurology. 48: 515-9. PMID 9040748 DOI: 10.1212/Wnl.48.2.515 |
0.369 |
|
| 1997 |
Sugihara S, Saunders AM, Ogawa A, Nakazato Y, Saido TC, Yamaguchi H. Characteristics of cerebral ? amyloid deposition in four non-demented patients in their forties with a high apolipoprotein E ?4 allele frequency Neuropathology. 17: 326-333. DOI: 10.1111/J.1440-1789.1997.Tb00061.X |
0.388 |
|
| 1996 |
Strittmatter WJ, Burke JR, DeSerrano VS, Huang DY, Matthew W, Saunders AM, Scott BL, Vance JM, Weisgraber KH, Roses AD. Protein: protein interactions in Alzheimer's disease and the CAG triplet repeat diseases. Cold Spring Harbor Symposia On Quantitative Biology. 61: 597-605. PMID 9246486 DOI: 10.1101/Sqb.1996.061.01.060 |
0.357 |
|
| 1996 |
Small GW, Komo S, La Rue A, Saxena S, Phelps ME, Mazziotta JC, Saunders AM, Haines JL, Pericak-Vance MA, Roses AD. Early detection of Alzheimer's disease by combining apolipoprotein E and neuroimaging. Annals of the New York Academy of Sciences. 802: 70-8. PMID 8993486 DOI: 10.1111/J.1749-6632.1996.Tb32600.X |
0.495 |
|
| 1996 |
Haines JL, Pritchard ML, Saunders AM, Schildkraut JM, Growdon JH, Gaskell PC, Farrer LA, Auerbach SA, Gusella JF, Locke PA, Rosi BL, Yamaoka L, Small GW, Conneally PM, Roses AD, et al. No association between alpha 1-antichymotrypsin and familial Alzheimer's disease. Annals of the New York Academy of Sciences. 802: 35-41. PMID 8993482 DOI: 10.1111/J.1749-6632.1996.Tb32596.X |
0.489 |
|
| 1996 |
Xu PT, Schmechel D, Rothrock-Christian T, Burkhart DS, Qiu HL, Popko B, Sullivan P, Maeda N, Saunders AM, Roses AD, Gilbert JR. Human apolipoprotein E2, E3, and E4 isoform-specific transgenic mice: human-like pattern of glial and neuronal immunoreactivity in central nervous system not observed in wild-type mice. Neurobiology of Disease. 3: 229-45. PMID 8980023 DOI: 10.1006/Nbdi.1996.0023 |
0.363 |
|
| 1996 |
Montine TJ, Huang DY, Valentine WM, Amarnath V, Saunders A, Weisgraber KH, Graham DG, Strittmatter WJ. Crosslinking of apolipoprotein E by products of lipid peroxidation. Journal of Neuropathology and Experimental Neurology. 55: 202-10. PMID 8786379 DOI: 10.1097/00005072-199602000-00009 |
0.421 |
|
| 1996 |
Okuizumi K, Onodera O, Seki K, Tanaka H, Namba Y, Ikeda K, Saunders AM, Pericak-Vance MA, Roses AD, Tsuji S. Lack of association of very low density lipoprotein receptor gene polymorphism with Caucasian Alzheimer's disease. Annals of Neurology. 40: 251-4. PMID 8773610 DOI: 10.1002/Ana.410400220 |
0.478 |
|
| 1996 |
Pritchard ML, Saunders AM, Gaskell PC, Small GW, Conneally PM, Rosi B, Yamaoka LH, Roses AD, Haines JL, Pericak-Vance MA. No association between very low density lipoprotein receptor (VLDL-R) and Alzheimer disease in American Caucasians. Neuroscience Letters. 209: 105-8. PMID 8761993 DOI: 10.1016/0304-3940(96)12630-6 |
0.46 |
|
| 1996 |
Saunders AM, Hulette O, Welsh-Bohmer KA, Schmechel DE, Crain B, Burke JR, Alberts MJ, Strittmatter WJ, Breitner JC, Rosenberg C. Specificity, sensitivity, and predictive value of apolipoprotein-E genotyping for sporadic Alzheimer's disease. Lancet (London, England). 348: 90-3. PMID 8676723 DOI: 10.1016/S0140-6736(96)01251-2 |
0.468 |
|
| 1996 |
Pericak-Vance MA, Johnson CC, Rimmler JB, Saunders AM, Robinson LC, D'Hondt EG, Jackson CE, Haines JL. Alzheimer's disease and apolipoprotein E-4 allele in an Amish population. Annals of Neurology. 39: 700-4. PMID 8651641 DOI: 10.1002/Ana.410390605 |
0.497 |
|
| 1996 |
Roses AD, Einstein G, Gilbert J, Goedert M, Han SH, Huang D, Hulette C, Masliah E, Pericak-Vance MA, Saunders AM, Schmechel DE, Strittmatter WJ, Weisgraber KH, Xi PT. Morphological, biochemical, and genetic support for an apolipoprotein E effect on microtubular metabolism. Annals of the New York Academy of Sciences. 777: 146-57. PMID 8624078 DOI: 10.1111/J.1749-6632.1996.Tb34413.X |
0.456 |
|
| 1996 |
Haines JL, Pritchard ML, Saunders AM, Schildkraut JM, Growdon JH, Gaskell PC, Farrer LA, Auerbach SA, Gusella JF, Locke PA, Rosi BL, Yamaoka L, Small GW, Conneally PM, Roses AD, et al. No genetic effect of alpha1-antichymotrypsin in Alzheimer disease. Genomics. 33: 53-6. PMID 8617509 DOI: 10.1006/Geno.1996.0158 |
0.498 |
|
| 1996 |
Lippa CF, Saunders AM, Smith TW, Swearer JM, Drachman DA, Ghetti B, Nee L, Pulaski-Salo D, Dickson D, Robitaille Y, Bergeron C, Crain B, Benson MD, Farlow M, Hyman BT, et al. Familial and sporadic Alzheimer's disease: neuropathology cannot exclude a final common pathway. Neurology. 46: 406-12. PMID 8614503 DOI: 10.1212/Wnl.46.2.406 |
0.35 |
|
| 1996 |
Roses A, Saunders A, Pericak-Vance M, Einstein G, Hulette C, Schmechel D, Huang D, Strittmatter W. Apolipoprotein is a susceptibility genetic locus that affects the expression of late-onset familial and sporadic Alzheimer's disease Biological Psychiatry. 39: 562. DOI: 10.1016/0006-3223(96)84162-X |
0.424 |
|
| 1995 |
Breitner JC, Welsh KA, Helms MJ, Gaskell PC, Gau BA, Roses AD, Pericak-Vance MA, Saunders AM. Delayed onset of Alzheimer's disease with nonsteroidal anti-inflammatory and histamine H2 blocking drugs. Neurobiology of Aging. 16: 523-30. PMID 8544901 DOI: 10.1016/0197-4580(95)00049-K |
0.401 |
|
| 1995 |
Roses AD, Saunders AM, Alberts MA, Strittmatter WJ, Schmechel D, Gorder E, Pericak-Vance MA. Apolipoprotein E E4 allele and risk of dementia. Jama. 273: 374-5; author reply . PMID 7823377 DOI: 10.1001/Jama.1995.03520290026015 |
0.461 |
|
| 1995 |
Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Roses AD, Pericak-Vance MA, Small GW, Haines JL. The apolipoprotein E E4 allele and sex-specific risk of Alzheimer's disease. Jama. 273: 373-4. PMID 7823376 DOI: 10.1001/jama.1995.03520290025013 |
0.321 |
|
| 1995 |
Roses AD, Saunders AM, Corder EH, Pericak-Vance MA, Han SH, Einstein G, Hulette C, Schmechel DE, Holsti M, Huang D. Influence of the susceptibility genes apolipoprotein E-epsilon 4 and apolipoprotein E-epsilon 2 on the rate of disease expressivity of late-onset Alzheimer's disease. Arzneimittel-Forschung. 45: 413-7. PMID 7763336 |
0.393 |
|
| 1995 |
Breitner JC, Welsh KA, Gau BA, McDonald WM, Steffens DC, Saunders AM, Magruder KM, Helms MJ, Plassman BL, Folstein MF. Alzheimer's disease in the National Academy of Sciences-National Research Council Registry of Aging Twin Veterans. III. Detection of cases, longitudinal results, and observations on twin concordance. Archives of Neurology. 52: 763-71. PMID 7639628 DOI: 10.1001/Archneur.1995.00540320035011 |
0.475 |
|
| 1995 |
Corder EH, Saunders AM, Pericak-Vance MA, Roses AD. There is a pathologic relationship between ApoE-epsilon 4 and Alzheimer's disease. Archives of Neurology. 52: 650-1. PMID 7619017 DOI: 10.1001/Archneur.1995.00540310012003 |
0.474 |
|
| 1995 |
Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Rimmler JB, Locke PA, Conneally PM, Schmader KE, Tanzi RE. Apolipoprotein E, survival in Alzheimer's disease patients, and the competing risks of death and Alzheimer's disease. Neurology. 45: 1323-8. PMID 7617191 DOI: 10.1212/Wnl.45.7.1323 |
0.499 |
|
| 1995 |
Roses AD, Saunders A. Head injury, amyloid beta and Alzheimer's disease. Nature Medicine. 1: 603-4. PMID 7585131 DOI: 10.1038/Nm0795-603 |
0.342 |
|
| 1995 |
Huang DY, Weisgraber KH, Goedert M, Saunders AM, Roses AD, Strittmatter WJ. ApoE3 binding to tau tandem repeat I is abolished by tau serine262 phosphorylation. Neuroscience Letters. 192: 209-12. PMID 7566652 DOI: 10.1016/0304-3940(95)11649-H |
0.36 |
|
| 1994 |
Strittmatter WJ, Weisgraber KH, Goedert M, Saunders AM, Huang D, Corder EH, Dong LM, Jakes R, Alberts MJ, Gilbert JR. Hypothesis: microtubule instability and paired helical filament formation in the Alzheimer disease brain are related to apolipoprotein E genotype. Experimental Neurology. 125: 163-71; discussion 1. PMID 8313935 DOI: 10.1006/Exnr.1994.1019 |
0.458 |
|
| 1994 |
Roses AD, Pericak-Vance MA, Saunders AM, Schmechel D, Goldgaber D, Strittmatter W. Complex genetic disease: can genetic strategies in Alzheimer's disease and new genetic mechanisms be applied to epilepsy? Epilepsia. 35: S20-8. PMID 8293721 DOI: 10.1111/J.1528-1157.1994.Tb05925.X |
0.405 |
|
| 1994 |
Han SH, Einstein G, Weisgraber KH, Strittmatter WJ, Saunders AM, Pericak-Vance M, Roses AD, Schmechel DE. Apolipoprotein E is localized to the cytoplasm of human cortical neurons: a light and electron microscopic study. Journal of Neuropathology and Experimental Neurology. 53: 535-44. PMID 8083695 DOI: 10.1097/00005072-199409000-00013 |
0.349 |
|
| 1994 |
Han SH, Hulette C, Saunders AM, Einstein G, Pericak-Vance M, Strittmatter WJ, Roses AD, Schmechel DE. Apolipoprotein E is present in hippocampal neurons without neurofibrillary tangles in Alzheimer's disease and in age-matched controls. Experimental Neurology. 128: 13-26. PMID 8070517 DOI: 10.1006/Exnr.1994.1108 |
0.477 |
|
| 1994 |
Sanan DA, Weisgraber KH, Russell SJ, Mahley RW, Huang D, Saunders A, Schmechel D, Wisniewski T, Frangione B, Roses AD. Apolipoprotein E associates with beta amyloid peptide of Alzheimer's disease to form novel monofibrils. Isoform apoE4 associates more efficiently than apoE3. The Journal of Clinical Investigation. 94: 860-9. PMID 8040342 DOI: 10.1172/Jci117407 |
0.302 |
|
| 1994 |
Strittmatter WJ, Saunders AM, Goedert M, Weisgraber KH, Dong LM, Jakes R, Huang DY, Pericak-Vance M, Schmechel D, Roses AD. Isoform-specific interactions of apolipoprotein E with microtubule-associated protein tau: implications for Alzheimer disease. Proceedings of the National Academy of Sciences of the United States of America. 91: 11183-6. PMID 7972031 DOI: 10.1073/Pnas.91.23.11183 |
0.388 |
|
| 1994 |
Corder EH, Saunders AM, Risch NJ, Strittmatter WJ, Schmechel DE, Gaskell PC, Rimmler JB, Locke PA, Conneally PM, Schmader KE. Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease. Nature Genetics. 7: 180-4. PMID 7920638 DOI: 10.1038/Ng0694-180 |
0.506 |
|
| 1994 |
Roses AD, Strittmatter WJ, Pericak-Vance MA, Corder EH, Saunders AM, Schmechel DE. Clinical application of apolipoprotein E genotyping to Alzheimer's disease. Lancet. 343: 1564-5. PMID 7911881 DOI: 10.1016/S0140-6736(94)92960-2 |
0.336 |
|
| 1994 |
Huang DY, Goedert M, Jakes R, Weisgraber KH, Garner CC, Saunders AM, Pericak-Vance MA, Schmechel DE, Roses AD, Strittmatter WJ. Isoform-specific interactions of apolipoprotein E with the microtubule-associated protein MAP2c: implications for Alzheimer's disease. Neuroscience Letters. 182: 55-8. PMID 7891887 DOI: 10.1016/0304-3940(94)90204-6 |
0.412 |
|
| 1994 |
Roses AD, Saunders AM. APOE is a major susceptibility gene for Alzheimer's disease. Current Opinion in Biotechnology. 5: 663-7. PMID 7765750 DOI: 10.1016/0958-1669(94)90091-4 |
0.444 |
|
| 1993 |
Strittmatter WJ, Saunders AM, Schmechel D, Pericak-Vance M, Enghild J, Salvesen GS, Roses AD. Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proceedings of the National Academy of Sciences of the United States of America. 90: 1977-81. PMID 8446617 DOI: 10.1073/Pnas.90.5.1977 |
0.47 |
|
| 1993 |
Schmechel DE, Saunders AM, Strittmatter WJ, Crain BJ, Hulette CM, Joo SH, Pericak-Vance MA, Goldgaber D, Roses AD. Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease. Proceedings of the National Academy of Sciences of the United States of America. 90: 9649-53. PMID 8415756 DOI: 10.1073/Pnas.90.20.9649 |
0.437 |
|
| 1993 |
Strittmatter WJ, Weisgraber KH, Huang DY, Dong LM, Salvesen GS, Pericak-Vance M, Schmechel D, Saunders AM, Goldgaber D, Roses AD. Binding of human apolipoprotein E to synthetic amyloid beta peptide: isoform-specific effects and implications for late-onset Alzheimer disease. Proceedings of the National Academy of Sciences of the United States of America. 90: 8098-102. PMID 8367470 DOI: 10.1073/Pnas.90.17.8098 |
0.302 |
|
| 1993 |
Saunders AM, Strittmatter WJ, Schmechel D, George-Hyslop PH, Pericak-Vance MA, Joo SH, Rosi BL, Gusella JF, Crapper-MacLachlan DR, Alberts MJ. Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer's disease. Neurology. 43: 1467-72. PMID 8350998 DOI: 10.1212/Wnl.43.8.1467 |
0.5 |
|
| 1993 |
Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, Roses AD, Haines JL, Pericak-Vance MA. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science (New York, N.Y.). 261: 921-3. PMID 8346443 DOI: 10.1126/Science.8346443 |
0.51 |
|
| 1993 |
Saunders AM, Roses AD. Apolipoprotein E4 allele frequency, ischemic cerebrovascular disease, and Alzheimer's disease. Stroke; a Journal of Cerebral Circulation. 24: 1416-7. PMID 8129809 |
0.324 |
|
| 1993 |
Saunders AM, Schmader K, Breitner JC, Benson MD, Brown WT, Goldfarb L, Goldgaber D, Manwaring MG, Szymanski MH, McCown N. Apolipoprotein E epsilon 4 allele distributions in late-onset Alzheimer's disease and in other amyloid-forming diseases. Lancet. 342: 710-1. PMID 8103823 DOI: 10.1016/0140-6736(93)91709-U |
0.396 |
|
| Show low-probability matches. |